Arbutus Biopharma vs Xencor
ABUS and XNCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABUS and XNCR compare
Xencor is the larger company, worth 3.3 times as much as Arbutus Biopharma ($2.6B against $799M).
Arbutus Biopharma grew revenue faster over the last twelve months (1079% versus −28.6% for Xencor).
Arbutus Biopharma keeps more of each dollar of sales as profit, with a net margin of 84.2% compared with −156% at Xencor.
Arbutus Biopharma scores higher on the StockData Score (14 against 5 for Xencor), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABUS | XNCR |
|---|---|---|
| Size and price | ||
| Market cap | $799M | $2.6B |
| Share price | $4.04 | $35.40 |
| Change, 1 year | −11.4% | 153% |
| Change, 5 years | 29.1% | −0.11% |
| Beta (5Y) | 1.29 | −0.09 |
| Employees | 19 | 260 |
| StockData Score | ||
| Total score | 14 (better) | 5 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 4 (better) | 1 |
| Health score | 6 (better) | 3 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 5.2× | – |
| P/S | 4.4× (better) | 25.1× |
| P/B | 3.1× (better) | 5.2× |
| EV/EBITDA | 4.7× | – |
| FCF yield | – | −7.9% |
| Fair value | $15.28 | $11.73 |
| Margin of safety | 73.6% (better) | −202% |
| Growth | ||
| Revenue growth (TTM) | 1079% (better) | −28.6% |
| Revenue growth, 5Y average | 15.3% (better) | 0.47% |
| Profitability | ||
| Operating margin | 82.0% (better) | −206% |
| Net margin | 84.2% (better) | −156% |
| FCF margin | – | −198% |
| Return on equity | 89.6% (better) | −29.1% |
| Return on invested capital | 156% (better) | −26.6% |
| Financial health | ||
| Debt / equity | 0.00 | 0.21 (better) |
| Interest coverage | 1960× (better) | −8.0× |
| Current ratio | 81.42 (better) | 6.39 |
| Altman Z-score | 28.79 (better) | 5.19 |
| Piotroski F-score | 4 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 71.1% | 113% |
| Held by insiders | 35.9% | 1.6% |
| Insider net buying, 12 months | – | −$7.5M |
| Short interest, % of float | 15.7% | 17.6% |
Go deeper
- ABUS stock overview
- ABUS income statement
- ABUS valuation and score
- XNCR stock overview
- XNCR income statement
- XNCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.